The Cancer Letter

Inside information on cancer research and drug development

In Brief

Charles Edward Geyer named co-director of NCI NCTN efforts at UPMC Hillman Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Charles Edward Geyer Jr. will join UPMC Hillman Cancer Center as co-director of its NCI National Clinical Trials Network efforts. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Carvykti extended OS in r/r MM vs standard therapies in phase III trial

Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account